SCHEMBL4908846

SCHEMBL4908846

CS(=O)(=O)Nc1cccc(Nc2nc(NCc3ccccc3O)c3nc[nH]c3n2)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 11/20 0.44
PDE5A O76074 2/20 0.40
JAK3 P52333 2/20 0.40
JAK2 O60674 1/20 0.40
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
CYP1A2 P05177 4/20 0.39
CYP3A4 P08684 4/20 0.39
CYP2C19 P33261 4/20 0.39
USP2 O75604 3/20 0.39
CYP2D6 P10635 3/20 0.39
CLK4 Q9HAZ1 3/20 0.39
HSD17B10 Q99714 2/20 0.39
CYP2C9 P11712 3/20 0.39
MAPK1 P28482 2/20 0.39
HIF1A Q16665 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4916831 0.91 PTK2 (0.44) PTK2PDE5AJAK3CYP1A2CYP3A4
SCHEMBL4696226 0.89 PTK2 (0.45) PTK2PDE5AJAK3CYP1A2CYP3A4
SCHEMBL4916374 0.87 PDE5A (0.50) PTK2PDE5AMAPTCYP1A2CYP3A4
SCHEMBL4919702 0.85 PDE5A (0.42) PTK2PDE5AMAPTHPGDCYP1A2
SCHEMBL4914819 0.85 PDE5A (0.44) PTK2PDE5AJAK3JAK2CYP1A2
SCHEMBL4916910 0.84 LRRK2 (0.50) PTK2JAK3MAPTKDM4EKMT2A
SCHEMBL4914617 0.83 TAAR1 (0.40) PTK2PDE5AJAK3CYP1A2CYP3A4
SCHEMBL4914810 0.82 PTK2 (0.41) PTK2JAK3JAK2JAK1
SCHEMBL4920898 0.82 PDE5A (0.45) PTK2PDE5AJAK3JAK1
SCHEMBL4912787 0.82 PTK2 (0.51) PTK2PDE5AHPGDCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK PTK2 1036/4885PDE5A 1383/4885JAK3 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.